(NASDAQ: OCGN) Ocugen's forecast annual revenue growth rate of 168.32% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 63.02%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.2%.
Ocugen's revenue in 2025 is $4,055,000.On average, 1 Wall Street analysts forecast OCGN's revenue for 2026 to be $321,215,917, with the lowest OCGN revenue forecast at $321,215,917, and the highest OCGN revenue forecast at $321,215,917. On average, 1 Wall Street analysts forecast OCGN's revenue for 2027 to be $29,674,510,441, with the lowest OCGN revenue forecast at $29,674,510,441, and the highest OCGN revenue forecast at $29,674,510,441.
In 2028, OCGN is forecast to generate $89,043,972,337 in revenue, with the lowest revenue forecast at $89,043,972,337 and the highest revenue forecast at $89,043,972,337.